UK Patient Feedback

Melanoma Focus have been invited by the Scottish Medicines Consortium to provide patient feedback to support the review of pembrolizumab in stage 2B and 2C melanoma in Scotland. This treatment has already been approved for this indication by NICE [TA837] and published in October 2022. If you have been treated with pembrolizumab (or an alternative treatment) in the UK for stage 2B or 2C melanoma (within a trial or since NICE approved), we invite you to complete the short questionnaire which should take about 10 minutes to complete – thank you.

This survey is now closed thank you for taking the time to complete it!